NCT05600127招募中2 期
Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer: the CHASIT Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 64
- 试验地点
- 4
- 主要终点
- Pathological complete response rate
研究概览
简要总结
Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
详细描述
Patients with locally advanced or clinically node positive urothelial carcinoma of the bladder, ureter or urethra (cT4NxM0 or cTxN1-N3M0) with at least stable disease after treatment with 3-4 cycles of platinum-based chemotherapy, will be treated with 3 cycles of avelumab (anti-PD-L1). If there are no signs of disease progression after avelumab treatment, radical surgery of the primary tumor and a pelvic lymph node dissection will follow.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
single arm study, therefore no masking possible
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Have histologically confirmed urothelial carcinoma of the bladder, upper urinary tract or urethra; a maximum of 50% of aberrant histology is allowed.
- •Have clinical stage cT4NxM0 or cTxN1-N3M0 as assessed by bimanual examination under anaesthesia, CT scan, MRI scan or PET-CT scan.
- •Have at least stable disease after a minimum of 3 or a maximum of 4 cycles of induction chemotherapy with cisplatin / carboplatin + gemcitabine according to RECIST v1.
- •Are fit and willing to undergo radical surgery with removal of lymph node template including all affected lymph nodes and the primary tumor.
- •World Health Organisation performance status of 0-
- •Provide written informed consent.
- •Negative pregnancy test in women with childbearing potential.
- •Adequate bone marrow function, including:
- •Absolute neutrophil count (ANC) ≥1,500/mm3 or 1.5 x 109/L;
- •Platelets ≥100 x 109/L;
- •Hemoglobin ≥5.6 mmol/L (may have been transfused).
- •Adequate renal function, defined as estimated creatinine clearance ≥30 mL/min as calculated by the CKD-EPI eGFR.
- •Adequate liver function, including:
- •Total serum bilirubin <1.5 x upper limit of normal (ULN);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 x ULN.
排除标准
- •Predominant (>50%) non-urothelial carcinoma histology in the diagnostic endoresection specimen of the bladder, urethra or upper urinary tract.
- •Any test for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating acute or chronic infection.
- •Have an estimated creatinin clearance as assessed by the CKD-EPI eGFR of <30 ml/min.
- •Prior exposure to immune-mediated therapy with exclusion of Bacillus-Calmette Guérin intravesical instillations, including but not limited to other anti-CTLA-4, anti PD-1, anti PD-L1, or anti-PD-L2 antibodies.
- •Persisting toxicity related to prior chemotherapy (Grade >2 NCI CTCAE v5.0).
- •A diagnosis of any other malignancy within 2 years prior to inclusion, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease.
- •≤2 cycles of induction platinum-based chemotherapy received.
- •Progression of disease during or following induction platinum-based chemotherapy, as assessed by RECIST v1.
- •Distant metastatic disease.
- •Previous pelvic radiation therapy.
- •Breastfeeding women.
- •Bilateral upper urinary tract urothelial carcinoma.
- •Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
- •Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
- •Active infection requiring systemic therapy.
- •Known severe hypersensitivity reactions to monoclonal antibodies (Grade 3), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of asthma symptom control per the Global Initiative for Asthma 2015).
- •Known prior or suspected hypersensitivity to avelumab.
- •Current use of immunosuppressive medication, EXCEPT the following:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection);
- •Systemic corticosteroids at (equivalent) doses of maximum 10 mg prednisone;
- •Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
- •Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy, or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivate vaccines (for example, inactivated influenza vaccines) or mRNA vaccines (for example, COVID-19 vaccines).
- •Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, and pneumonitis; psychiatric condition including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究组 & 干预措施
Avelumab
Experimental
3 cycles of avelumab (Bavencio), 800mg intravenous instillation in 60 min, every 2 weeks.
干预措施: Avelumab (Drug)
结局指标
主要结局
Pathological complete response rate
时间窗: About 1 month after radical surgery
the proportion of patients without residual UC in the surgical resection specimen, ypT0N0 (carcinoma situ is allowed), in the intention-to-treat analysis.
次要结局
- Survival(24 months after radical surgery)
- Surgical complications(90 days after radical surgery)
- Non-invasive urothelial cancer(About 1 month after radical surgery)
- Adverse events(90 days after administration of the last cycle of avelumab)
- Delay in surgery(About 1 month after radical surgery)
研究者
J.L. Boormans, MD PhD
Principal Investigator
Erasmus Medical Center
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
2 期
Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)Lung Cancer, Non-small CellNCT05784142Jiangsu Cancer Institute & Hospital55
招募中
2 期
CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT studybladder/upper urinary tract/urethra cancerUrothelial cancer10038364NL-OMON53642Erasmus MC, Universitair Medisch Centrum Rotterdam58
招募中
1 期
CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT studyrothelial cancer of the bladder, upper urinary tract or urethra.MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864EUCTR2022-000514-33-NLErasmus MC58
招募中
3 期
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)Bladder Urothelial CarcinomaBladder CancerNCT04574960University Health Network, Toronto14
进行中（未招募）
2 期
CIK in Treating Patients With Bladder CancerUrinary Bladder NeoplasmsNCT02489890The First People's Hospital of Changzhou1,500